United States - English - NLM (National Library of Medicine)

bryant ranch prepack - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 2 mg - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) the mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin d intake, and when indicated, pharmacologic therapy. postmenopausal women require an average of 1500 mg/day of elemental calcium. therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. vitamin d supplementation of 400 to 800 iu/day may also be required to ensure adequate daily intake in postmenopausal women. estrogens should not be used in individuals with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected or history of cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction. - liver dysfunction or disease. - estradiol tablets should not be used in patients with known hypersensitivity to its ingredients. estradiol tablets 2 mg contain fd&c yellow no. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. although the overall incidence of fd&c yellow no. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. - known or suspected pregnancy. there is no indication for estradiol tablets in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions .)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

besins healthcare sa-nv - estradiol hemihydrate 0,775 mg/dose - eq. estradiol 0,75 mg/dose - transdermal gel - 0,75 mg/dose - estradiol hemihydrate 0.775 mg/dose - estradiol

United States - English - NLM (National Library of Medicine)

alvogen, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.025 mg in 1 d -     when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered.     when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered. the estradiol transdermal system is contraindicated in women with any of the following conditions: the estradiol transdermal system should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as oral contraceptives inadvertently during early pregnancy. the estradiol transdermal system should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogens have been identified in the b

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ethinylestradiol 0,03 mg; drospirenone 3 mg - tablet - 0,03 mg - 3 mg - ethinylestradiol 0.03 mg; drospirenone 3 mg - drospirenone and ethinylestradiol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ethinylestradiol 0,02 mg; drospirenone 3 mg - tablet - 0,02 mg - 3 mg - ethinylestradiol 0.02 mg; drospirenone 3 mg - drospirenone and ethinylestradiol

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - oestradiol benzoate - parenteral liquid/solution/suspension - oestradiol benzoate steroid-estrogen active 1.0 mg/ml - endocrine system - cattle - adult | heifer | bovine - fertility problems | stimulate ovulation | anoestrus | oestrus cycle | ovarian cysts | promote ovulation | superovulation

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - oestradiol 17 beta - parenteral implant, device - oestradiol 17 beta steroid-estrogen active 21.1 mg/do - nutrition & metabolism - heifer (young female cattle) | heifer speyed (neutered young cow) | steer (castrated male cattle) | beef | bovine | bullock (you - promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - oestradiol 17 beta - parenteral implant, device - oestradiol 17 beta steroid-estrogen active 43.9 mg/do - nutrition & metabolism - heifer (vealer) | heifer speyed (neutered young cow) | steer (castrated male cattle) | beef | bovine | bullock (young) | male ca - promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - oestradiol 17 beta - parenteral implant, device - oestradiol 17 beta steroid-estrogen active 25.7 mg/do - nutrition & metabolism - heifer (vealer) | heifer speyed (neutered young cow) | steer (castrated male cattle) | beef | bovine | bullock (young) | male ca - promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

New Zealand - English - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - ethinylestradiol 0.01mg - tablet - 0.01 mg - active: ethinylestradiol 0.01mg excipient: acacia alginic acid ethanol lactose monohydrate magnesium stearate potato starch water - postmenopausal symptoms due to oestrogen deficiency including prevention of postmenopausal osteoporosis. in women with an intact uterus the addition of a progestogen is essential